About Amineptine Hydrochloride

Severe acne due to amineptine was first reported in 1988 , to name a few—simultaneously in the same issue of Annales de dermatologie et de vénéréologie and in 12 March 1988 of The Lancet. A year later, Dr Martin-Ortega and colleagues in Barcelona, Spain reported a case of "acneiform eruption" in a 54-year-old woman whose intake of amineptine was described as "excessive."[13] One year after that, Vexiau and colleagues reported six women, one of whom never admitted to using amineptine, getting severe acne concentrated in the face, back and thorax, the severity of which varied with the dosage. Most of them were treated unsuccessfully with isotretinoin (Accutane) for about 18 months; two of the three that discontinued amineptine experienced a reduction in cutaneous symptoms, with the least affected patient going into remission.
This can be seen as a general side effect of central dopamine enhancement, due to the inhibitory effect of dopamine on prolactin, with the subsequent increase in testosterone output, leading in turn to the same potential for acne as is typical of pubescents.
Amineptine Hydrochloride
CAS No.:30272-08-3
Synonyms: 7-[(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid hydrochloride
Molecular Formula:  C22H27NO2.HCl
Molecular Weight: 373.92
Canonical SMILES: C1(c2c(CCc3c1cccc3)cccc2)[NH2+]CCCCCCC(O)=O.[ClH-]